Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.48 |
| ▸ | F13A1 | P00488 | 1/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.42 |
| ▸ | FLT3 | P36888 | 6/20 | 0.40 |
| ▸ | KIT | P10721 | 4/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.40 |
| ▸ | FLT4 | P35916 | 4/20 | 0.40 |
| ▸ | KDR | P35968 | 4/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.40 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.40 |
| ▸ | FLT1 | P17948 | 3/20 | 0.40 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
| ▸ | GEMIN4 | P57678 | 1/20 | 0.39 |
| ▸ | HSF1 | Q00613 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pochoxime C SCHEMBL12384141 | 1.00 | MKNK2 (0.48) | MKNK2F13A1TGM2HSP90AB1MKNK1 | |
| Pochoxime C SCHEMBL4514408 | 1.00 | MKNK2 (0.48) | MKNK2F13A1TGM2HSP90AB1MKNK1 | |
| SCHEMBL12384139 | 0.93 | MKNK2 (0.42) | MKNK2F13A1TGM2HSP90AB1MKNK1 | |
| SCHEMBL13770506 | 0.93 | MKNK2 (0.42) | MKNK2F13A1TGM2HSP90AB1MKNK1 | |
| SCHEMBL15447994 | 0.90 | MKNK2 (0.43) | MKNK2F13A1TGM2HSP90AB1MKNK1 | |
| SCHEMBL12252662 | 0.90 | MKNK2 (0.43) | MKNK2F13A1TGM2HSP90AB1MKNK1 | |
| SCHEMBL12252659 | 0.90 | MKNK2 (0.43) | MKNK2F13A1TGM2HSP90AB1MKNK1 | |
| SCHEMBL15447997 | 0.90 | MKNK2 (0.43) | MKNK2F13A1TGM2HSP90AB1MKNK1 | |
| SCHEMBL12253244 | 0.90 | MKNK2 (0.43) | MKNK2F13A1TGM2HSP90AB1MKNK1 | |
| SCHEMBL12253248 | 0.90 | MKNK2 (0.43) | MKNK2F13A1TGM2HSP90AB1MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10239856-B2 | Synthesis of resorcylic acid lactones useful as therapeutic agents | UNIVERSITY DE STRASBOURG (FR) | 2019-03-26 | — | — | US | disclosed |
| WO-2017133517-A1 | PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF | 四川海思科制药有限公司 | 2017-08-10 | — | — | WO | disclosed |
| US-20170174669-A1 | POCHOXIME CONJUGATES USEFUL FOR THE TREATMENT OF HSP90 RELATED PATHOLOGIES | UNIV STRASBOURG (FR) | 2017-06-22 | — | — | US | disclosed |
| EP-2242359-B1 | SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS | UNIV STRASBOURG (FR) | 2016-06-01 | — | — | EP | disclosed |
| US-20160075677-A1 | SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS | UNIVERSITE DE STRASBOURG (FR) | 2016-03-17 | — | — | US | disclosed |
| US-20150374680-A1 | POCHOXIME CONJUGATES USEFUL FOR THE TREATMENT OF HSP90 RELATED PATHOLOGIES | UNIVERSITE DE STRASBOURG (FR) | 2015-12-31 | — | — | US | disclosed |
| US-9051302-B2 | Synthesis of resorcylic acid lactones useful as therapeutic agents | UNIVERSITE DE STRASBOURG (FR) | 2015-06-09 | — | — | US | disclosed |
| US-9051302-B2 | Synthesis of resorcylic acid lactones useful as therapeutic agents | UNIVERSITE DE STRASBOURG (FR) | 2015-06-09 | — | — | US | disclosed |
| US-20140031302-A1 | POCHOXIME CONJUGATES USEFUL FOR THE TREATMENT OF HSP90 RELATED PATHOLOGIES | UNIVERSITE DE STRASBOURG (FR) | 2014-01-30 | — | — | US | disclosed |
| US-8329683-B2 | Treatment of neurofibromatosis with radicicol and its derivatives | NEXGENIX PHARMACEUTICALS, LLC (US) | 2012-12-11 | — | — | US | disclosed |
| WO-2012052843-A1 | POCHOXIME CONJUGATES USEFUL FOR THE TREATMENT OF HSP90 RELATED PATHOLOGIES | UNIVERSITE DE STRASBOURG (FR) | 2012-04-26 | — | — | WO | disclosed |
| US-20110217335-A1 | SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS | UNIVERSITE DE STRASBOURG (FR) | 2011-09-08 | — | — | US | disclosed |
| US-20110217335-A1 | SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS | UNIVERSITE DE STRASBOURG (FR) | 2011-09-08 | — | — | US | disclosed |
| US-20100292218-A1 | Treatment Of Neurofibromatosis With Radicicol And Its Derivatives | NEXGENIX PHARMACEUTICALS HOLDINGS, INC. | 2010-11-18 | — | — | US | disclosed |
| US-20100292218-A1 | Treatment Of Neurofibromatosis With Radicicol And Its Derivatives | NEXGENIX PHARMACEUTICALS HOLDINGS, INC. | 2010-11-18 | — | — | US | disclosed |
| WO-2009091921-A1 | SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS | UNIVERSITE DE STRASBOURG (FR) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174669-A1 | POCHOXIME CONJUGATES USEFUL FOR THE TREATMENT OF HSP90 RELATED PATHOLOGIES | HSP90AB2P, HSP90AB1, HSP90AA1 | MKNK2 59/4885F13A1 3892/4885TGM2 721/4885 |
| US-20150374680-A1 | POCHOXIME CONJUGATES USEFUL FOR THE TREATMENT OF HSP90 RELATED PATHOLOGIES | HSP90AB2P, HSP90AB1, HSP90AA1 | MKNK2 56/4885F13A1 4287/4885TGM2 415/4885 |
| US-20100292218-A1 | Treatment Of Neurofibromatosis With Radicicol And Its Derivatives | HSP90AB2P, HSP90AA1, HSPA2 | MKNK2 2172/4885F13A1 764/4885TGM2 1861/4885 |
| US-20110217335-A1 | SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS | HSP90AA1, HSP90AB1, HSP90AB2P | MKNK2 60/4885F13A1 3830/4885TGM2 2199/4885 |
| US-10239856-B2 | Synthesis of resorcylic acid lactones useful as therapeutic agents | HSP90AA1, HSP90AB1, HSP90AB2P | MKNK2 60/4885F13A1 3830/4885TGM2 2199/4885 |
| US-20160075677-A1 | SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS | HSP90AA1, HSP90AB1, HSP90AB2P | MKNK2 60/4885F13A1 3830/4885TGM2 2199/4885 |
| US-20140031302-A1 | POCHOXIME CONJUGATES USEFUL FOR THE TREATMENT OF HSP90 RELATED PATHOLOGIES | HSP90AB2P, HSP90AB1, HSP90AA1 | MKNK2 59/4885F13A1 3892/4885TGM2 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.